Education
About Us
Working with TipRanks
Follow Us
Hyperion DeFi (HYPD)
NASDAQ:HYPD
Tropicamide-Phenylephrine Fixed Combination Ophthalmic Solution
Mydriasis
Phase IV
Completed
Evaluation of Pupil Dilation Speed With the MAP Dispenser
May 25, 2021
―
Atropine 0.1% Ophthalmic Solution, Atropine 0.01% Ophthalmic Solution
Myopia
Phase III
Terminated
Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression
May 07, 2019
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Hyperion DeFi (HYPD) have in its pipeline
HYPD is currently developing the following drugs: Tropicamide-Phenylephrine Fixed Combination Ophthalmic Solution, Atropine 0.1% Ophthalmic Solution, Atropine 0.01% Ophthalmic Solution. These drug candidates are in various stages of clinical development as the company works toward FDA approval.